Highest Quality, Top‑Tier iPSC‑Derived Cells
- Adherence to exceptional quality through our robust QA assays.
- Confirm the identity, activity and phenotypic relevance.
- Pioneers in the commercialization of iPSCs.
- Tenure and diverse differentiation experience solidifies Ncardia as true iPSC experts. Deliver quality on-time.
Deep Understanding of iPSC Applications
- Expertise in diseases biology, modeling and progression and uniquely couples the disease model to our iPSC technology.
- Experience with various therapeutics modalities.
- Integrated iPSC-based drug discovery platform that allows pharmaceutical companies to mimic drug interactions with the human body from hit identification to lead optimization leveraging its large-scale manufacturing capabilities to ensure reproducible high-throughput screenings.
Excellent Customer Service
- A decade of experience and team with Ph.Ds.
- Significant expertise in iPSC technology and its applications in drug discovery & cell therapy.
- Complete support throughout the client experience, outstanding customer service. Flexible in adjusting to changed priorities.
- Proven track record of successful collaborations with major pharmaceutical companies of supporting multi-year drug discovery programs.
A History of iPSC Expertise
Formulation of Pluriomics, an iPSC-derived research product company, by Stefan Braam and Herman Spolders, together with the scientific founders Prof. Dr. Mummery and Prof. Dr. Passier.
First iPSC-based drug discovery screening activities performed
Ncardia was formed in August 2017 following an acquisition by Pluriomics
Launch of Ncardia’s large-scale iPSC manufacturing platform
$60 million investment as part of a strategic partnership with Kiniciti to expand our drug discovery offerings
Cellistic, an affiliate company focused on iPSC-based cell therapy, is formed to capitalize on Ncardia’s large-scale manufacturing expertise and proven processes in iPSC differentiation
Ncardia moves into new, larger offices - providing space for our growing team, doubling our lab area and quadrupling bioreactor capacity - to expand capabilities and facilitate longer and more comprehensive programs.